Data of the research work: Expression and localization of delta and kappa opioid receptors in human endometrium during the menstrual cycle

Olabarrieta et al. 2022. Supplementary data Table 1. Primary data for HSCORE values representing the immunoreactivity intensity of DOR protein staining in the stromal compartment. Phase I Phase II Phase III Phase IV Phase V 1,891 1,709 1,836 2,024 1,626 2,016 1,862 2,06 2,057 1,863 1,941 2,121 2,14 2,165 1,952 2,022 1,939 1,838 1,92 1,6 1,942 2 2,164 2,126 1,915 1,674 1,933 1,905 2,049 1,78 1,542 1,662 1,888 1,838 1,862 1,903 1,381 1,833 2,197 1,765 1,562 1,791 1,825 1,901 1,851 1,677 1,868 1,821 1,729 1,974 1,923 2,264 1,9 1,527 1,894 1,911 1,845 1,912 2,045 1,897 1,919 1,918 2,124 1,367 2,376 2,008 1,479 2,22 2,087 1,693 2,343 2,384 2,263 2,232 2,46 2,33 Olabarrieta et al. 2022. Supplementary data Table 2. Primary data for HSCORE values representing the immunoreactivity intensity of DOR protein staining in the epithelial glands. Phase I Phase II Phase III Phase IV Phase V 2,026 2,029 2,24 2,185 2,025 1,833 1,572 2,114 2,536 2,023 2,065 1,878 2,127 2,541 2,337 1,776 1,925 2,055 2,417 2,015 2,028 2,024 2,803 2,748 1,926 2,05 1,618 2,397 2,503 2,019 1,91 1,481 2,347 2,046 2,22 2,04 1,593 2,166 2,379 1,915 2,074 2,354 2,035 1,994 1,512 2,215 1,908 1,844 2,678 1,777 1,957 2,207 2,018 1,89 2,5 2,046 1,541 2,17 2,146 2,482 2,084 2,627 2,057 2,329 2,451 2,497 2,31 2,562 2,333 2 2,536 2,246 Olabarrieta et al. 2022. Supplementary data Table 3. Primary data for HSCORE values representing the immunoreactivity intensity of DOR protein staining in the luminal surface. Phase I Phase II Phase III Phase IV Phase V 2,775 1,995 3,143 2,425 2,315 2,862 1,872 2,516 2,853 2,36 3,297 1,49 3,157 2,759 2,455 3,069 1,889 2,066 3,056 2,006 3,273 1,895 2,039 2,791 2,127 2,978 1,979 2,041 2,955 2,513 1,363 2,157 2,501 2,2 1,512 2,382 2,226 1,73 2,181 2,295 1,951 2,736 2,665 1,844 2,587 2,642 1,821 2,8 2,503 1,887 3,086 1,997 2,721 1,5 3,11 2,764 2,982 2,869 Olabarrieta et al. 2022. Supplementary data Table 4. Primary data for HSCORE values representing the immunoreactivity intensity of DOR protein staining in the whole endometrium. Phase I Phase II Phase III Phase IV Phase V 2,775 1,995 3,143 2,425 2,315 2,862 1,872 2,516 2,853 2,36 3,297 1,49 3,157 2,759 2,455 3,069 1,889 2,066 3,056 2,006 3,273 1,895 2,039 2,791 2,127 2,978 1,979 2,041 2,955 2,513 1,891 1,363 2,157 2,501 2,2 2,016 1,512 2,382 2,024 2,226 1,941 1,73 2,181 2,057 2,295 2,022 1,951 2,736 2,165 2,665 1,942 1,844 2,587 1,92 2,642 1,674 1,821 2,8 2,126 2,503 1,542 1,887 3,086 2,049 1,626 1,903 1,997 2,721 1,838 1,863 1,562 1,5 3,11 2,197 1,952 2,026 1,709 2,764 1,901 1,6 1,833 1,862 2,982 2,185 1,915 2,065 2,121 2,869 2,536 1,78 1,776 1,939 1,836 2,541 1,862 2,028 2 2,06 2,417 1,765 2,05 1,933 2,14 2,748 1,851 1,91 1,662 1,838 2,503 1,821 2,04 1,381 2,164 2,046 1,923 1,791 1,905 2,379 1,527 1,677 1,888 2,035 1,845 1,729 1,833 1,897 2,264 1,825 2,124 1,894 1,868 2,008 1,912 1,974 2,087 1,919 1,9 2,025 1,367 1,911 2,023 1,479 2,045 2,337 1,693 1,918 2,015 2,029 2,376 1,926 1,572 2,22 2,019 1,878 2,343 2,22 1,925 2,384 1,915 2,024 2,263 1,994 1,618 2,232 1,908 1,481 2,46 1,777 1,593 2,33 2,018 2,074 2,24 2,046 Olabarrieta et al. 2022. Supplementary data 1,512 2,114 2,146 1,844 2,127 2,084 1,957 2,055 2,057 1,89 2,803 1,541 2,397 2,347 2,166 2,354 2,215 2,678 2,207 2,5 2,17 2,482 2,627 2,329 2,451 2,497 2,31 2,562 2,333 2 2,536 2,246 Olabarrieta et al. 2022. Supplementary data Table 5. Primary data for HSCORE values representing the immunoreactivity intensity of KOR protein staining in the stromal compartment. Phase I Phase II Phase III Phase IV Phase V 1,158 1,96 1,802 1,734 1,583 1,586 1,674 1,865 1,908 1,737 1,406 1,733 1,914 1,724 1,878 1,997 1,93 1,903 1,946 1,51 2,004 1,959 1,728 1,431 1,671 2,004 1,658 1,929 1,893 1,883 1,465 1,509 1,862 2,006 1,428 1,591 1,864 1,907 1,788 1,821 1,91 1,83 1,919 1,912 1,526 1,898 1,969 1,865 1,737 1,822 2,006 1,932 1,814 1,83 1,742 1,605 1,725 1,928 1,486 1,918 1,811 1,958 1,791 1,338 1,522 2,046 1,841 1,869 1,829 1,898 1,965 1,965 1,638 1,904 1,781 2,043 1,953 1,812 1,361 1,69 2,041 1,491 1,891 1,277 1,517 1,756 1,704 1,975 Table 6. Primary data for HSCORE values representing the immunoreactivity intensity of KOR protein staining in the gland epithelium. Phase I Phase II Phase III Phase IV Phase V 1,733 2,128 2,022 2,25 1,671 1,784 1,618 2,198 2,182 1,616 1,722 1,502 2,045 2,454 1,789 2,063 1,863 1,894 2,217 1,668 2,043 1,626 2,01 2,218 1,844 2,107 1,815 2,024 1,737 1,865 1,645 1,812 1,876 2,212 1,89 1,919 1,685 1,966 2,395 1,672 1,887 2,012 1,983 2,161 1,905 1,745 1,863 1,947 2,157 1,947 1,697 1,94 1,755 1,855 1,967 1,635 1,436 2,116 2,103 1,858 1,905 1,446 2,215 2,049 1,677 1,749 1,964 2,007 1,997 1,979 1,809 1,651 2,142 1,803 1,873 1,794 1,929 1,869 1,799 2,035 1,512 2,013 Olabarrieta et al. 2022. Supplementary data Table 7. Primary data for HSCORE values representing the immunoreactivity intensity of KOR protein staining in the luminal surface. Phase I Phase II Phase III Phase IV Phase V 1,683 1,507 1,941 2,609 2,045 1,944 1,831 1,969 2,621 2,109 1,877 1,649 1,972 2,612 2,185 1,747 1,621 2,126 2,725 2,02 1,679 1,532 2,147 2,694 2,182 1,984 1,745 2,126 2,957 2,019 1,294 1,689 1,993 2,733 1,827 1,713 1,441 1,877 2,28 2,386 1,349 1,768 1,898 2,564 2,203 1,491 1,935 2,098 1,745 1,775 1,893 2,543 1,921 1,773 2,81 1,912 2,139 2,669 2,105 2,157 2,329 2,126 2,409 2,062 2,034 2,08 2,438 2,513 Table 8. Primary data for HSCORE values representing the immunoreactivity intensity of KOR protein staining in the whole endometrium. Phase I Phase II Phase III Phase IV Phase V 1,158 1,96 1,802 1,734 1,583 1,586 1,674 1,865 1,908 1,737 1,406 1,733 1,914 1,724 1,878 1,997 1,93 1,903 1,946 1,51 2,004 1,959 1,728 1,431 1,671 2,004 1,658 1,929 1,893 1,883 1,465 1,509 1,862 2,006 1,428 1,591 1,864 1,907 1,788 1,821 1,092 1,83 1,919 1,912 1,526 1,91 1,969 1,865 1,737 1,822 1,898 1,932 1,286 1,83 1,742 2,006 1,725 1,814 1,486 1,918 1,605 1,958 1,928 1,338 1,522 1,811 1,841 1,791 1,829 1,898 2,046 1,965 1,869 1,904 1,781 1,965 1,953 1,638 1,361 1,69 2,043 1,491 1,812 1,277 1,517 2,041 1,756 1,891 1,704 1,975 1,733 2,128 2,022 2,25 1,671 Olabarrieta et al. 2022. Supplementary data 1,784 1,618 2,198 2,182 1,616 1,722 1,502 2,045 2,454 1,789 2,063 1,863 1,894 2,217 1,668 2,043 1,626 2,01 2,218 1,844 2,107 1,136 2,024 1,737 1,865 1,645 1,815 1,876 2,212 1,89 1,919 1,812 1,966 2,395 2,301 1,887 1,217 1,983 2,161 1,672 1,745 1,685 1,947 1,638 1,905 1,697 2,012 1,755 2,157 1,947 1,635 1,863 2,116 1,855 1,967 1,221 1,94 2,215 2,103 1,858 1,31 1,436 2,007 2,049 1,677 1,905 1,446 2,142 1,997 1,979 1,749 1,964 1,869 1,803 1,873 1,809 1,651 2,035 1,595 1,799 1,794 1,929 2,013 1,627 1,512 1,683 1,507 1,941 2,609 2,045 1,944 1,831 1,969 2,621 2,109 1,877 1,649 1,972 2,612 2,185 1,747 1,621 2,126 2,725 2,02 1,679 1,532 2,648 2,694 2,182 1,984 1,745 2,147 2,957 2,019 1,294 1,689 2,126 2,733 1,827 1,713 1,441 1,993 2,28 2,386 1,349 1,768 1,877 2,564 2,203 1,491 1,898 2,098 1,745 1,775 1,935 2,543 1,921 1,773 1,893 2,81 1,912 2,139 2,669 2,105 2,157 2,329 2,126 2,409 2,062 2,034 2,08 2,438 2,513